Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a Healthcare stock trading at $3.72 (as of 2026-08-21), with a market capitalization of $2.18M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Shuttle Pharmaceuticals Holdings, Inc., through Shuttle Pharmaceuticals, Inc., develops and commercializes oncology drugs designed to sensitize cancers to radiation therapy. Its clinical-stage pipeline includes Ropidoxuridine for brain tumors and soft tissue sarcomas and Doranidazole for pancreatic, lung, and liver cancers.

Understand Shuttle Pharmaceuticals Holdings, Inc.: how it makes money

Shuttle Pharmaceuticals develops and commercializes cancer drugs that sensitize tumors to radiation therapy, including clinical-stage candidates Ropidoxuridine (oral) and Doranidazole (injectable).

The profit model is tied to whether its clinical-stage radiosensitizer drug candidates (Ropidoxuridine, Doranidazole) successfully transition into approved, commercial products that generate sales.

Business quality (Weak): Clear focus on radiosensitizing oncology drugs, but investor visibility is limited here because no reportable segments or operating KPIs are provided.

Bull case

  • Focused drug strategy: The company focuses on drugs for sensitizing cancers to radiation therapy, centered on two clinical-stage products, Ropidoxuridine and Doranidazole.
  • Commercialization intent: Management’s stated goal includes discovery, development, and commercialization of these therapies, which links future value to successful regulatory and commercialization outcomes.

Bear case

  • Clinical-stage execution risk: Because its products are described as being in clinical stage, outcomes may depend on trial and regulatory progress for each candidate.
  • Currently unprofitable based on latest reported metrics: For the period ended 2026-03-31, operating margin is shown as deeply negative, indicating material operating losses in the reported data.
  • Limited disclosed operating KPIs and segment detail in the provided data: No operating KPIs or segment revenue breakdowns are provided here, which makes it harder to track operational drivers beyond the overall business description.
Valuation — source: SEC EDGAR (first-party)
Price$3.72
Market Cap$2.18M
Price / Book0.65
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1090.00
Net Margin-1075382.5%
Revenue Growth (YoY)-97.1%
EPS Growth (YoY)124.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-9.28 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderIkarian Capital, LLC ($46832.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOChristopher Robert Cooper
Employees9
CountryUS
IPO Date2022-08-31

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Ernexa Therapeutics Inc. (ERNA)
  • Nexentis Technologies Inc. (NXTS)
  • Onconetix, Inc. (ONCO)
  • HCW Biologics Inc. (HCWB)
  • Oragenics, Inc. (OGEN)
  • CDT Equity Inc. (CDT)
  • Jaguar Health, Inc. (JAGX)
  • Decoy Therapeutics Inc. (DCOY)
SHPH earnings history · SHPH institutional & insider holders · SHPH KPIs & operating metrics · SHPH financials · SHPH investor presentations & press releases · SHPH SEC filings · SHPH peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.